UK markets close in 7 hours 54 minutes
  • FTSE 100

    7,467.47
    +96.01 (+1.30%)
     
  • FTSE 250

    21,861.80
    +216.09 (+1.00%)
     
  • AIM

    1,090.19
    +5.98 (+0.55%)
     
  • GBP/EUR

    1.1960
    +0.0015 (+0.12%)
     
  • GBP/USD

    1.3512
    +0.0005 (+0.04%)
     
  • BTC-GBP

    27,820.60
    +954.04 (+3.55%)
     
  • CMC Crypto 200

    854.24
    +33.65 (+4.10%)
     
  • S&P 500

    4,356.45
    -53.68 (-1.22%)
     
  • DOW

    34,297.73
    -66.77 (-0.19%)
     
  • CRUDE OIL

    85.80
    +0.20 (+0.23%)
     
  • GOLD FUTURES

    1,845.70
    -6.80 (-0.37%)
     
  • NIKKEI 225

    27,011.33
    -120.01 (-0.44%)
     
  • HANG SENG

    24,289.90
    +46.29 (+0.19%)
     
  • DAX

    15,361.94
    +238.07 (+1.57%)
     
  • CAC 40

    6,934.24
    +96.28 (+1.41%)
     

3rd Quarter Results

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • OXT.L

Oxford Technology VCT Plc – 3rd Quarter Results

Oxford Technology VCT Plc presents its quarterly update for the 3 month period commencing 1 September 2021.

The Directors have recently reviewed the valuation of its entire portfolio as at 30 November 2021.

The unaudited net asset value per ordinary share as at 30 November 2021 was 50.3p. This represents a decrease of 1.1p from the net asset value per ordinary share at 31 August 2021. This decrease is mainly attributable to the fall in the share price of Scancell Plc (22.5p to 20.0p), but partially offset by the increase in the Arecor Therapeutics Plc share price (230p to 380p).

The total return to shareholders including previous dividends of 55.0p per share is now 105.3p per share.

The total number of ordinary shares in issue is 5,431,655.

The Directors are not aware of any other events or transactions which have taken place between 30 November 2021 and the publication of this statement which have had a material effect on the financial position of the Company.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a Regulatory Information Service, this information is now considered to be in the public domain.

7 January 2022

Enquiries:
Lucius Cary, Oxford Technology Management
01865 784466


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting